Your feedback matters and will make a difference. Help us understand your digital experience by taking our 10 minute survey. Your responses are completely anonymous. Start the survey.
Document
Summary
NHS England Evidence Review
Rituximab for acute immune thrombotic thrombocytopaenic purpura
Drafted: July 2021
Prepared by Solutions for Public Health (SPH) on behalf of NHS England Specialised Commissioning
Document
Summary
NHS England Evidence Review
Rituximab for prophylactic treatment for Thrombotic Thrombocytopaenic Purpura (TTP)
Drafted: July 2021
Prepared by Solutions for Public Health (SPH) on behalf of NHS England Specialised Commissioning